Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is 10.47% higher on its value in year-to-date trading and has touched a low of $2.21 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHAT stock was last observed hovering at around $8.83 in the last trading session, with the day’s gains setting it 0.14%.
Currently trading at $8.97, the stock is 83.99% and 104.37% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.46 million and changing 1.59% at the moment leaves the stock -2.29% off its SMA200. PHAT registered -7.33% loss for a year compared to 6-month loss of 5.53%. The firm has a 50-day simple moving average (SMA 50) of $4.3891 and a 200-day simple moving average (SMA200) of $9.180425.
The stock witnessed a 185.67% gain in the last 1 month and extending the period to 3 months gives it a 87.27%, and is 81.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 32.10% over the week and 15.19% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 427 employees, a market worth around $626.23M and $81.86M in sales. Profit margin for the company is -422.42%. Distance from 52-week low is 305.88% and -54.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-165.71%).
The EPS is expected to grow by 42.60% this year.
Phathom Pharmaceuticals Inc (PHAT) Top Institutional Holders
195.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 89.54% of the company’s shares. The shares outstanding are 69.64M, and float is at 37.85M with Short Float at 29.53%. Institutions hold 85.70% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.2637% of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.7473 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9715% and valued at over $35.84 million, while INVESCO LTD. holds 5.3681 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider purchase by Topper James N, the company’s Director. SEC filings show that Topper James N bought 3,780 shares of the company’s common stock on May 21 ’25 at a price of $3.86 per share for a total of $14609.0. Following the purchase, the insider now owns 59403.0 shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on May 14 ’25 that Topper James N (Director) bought a total of 6,300 shares of the company’s common stock. The trade occurred on May 14 ’25 and was made at $3.32 per share for $20919.0. Following the transaction, the insider now directly holds 55623.0 shares of the PHAT stock.
Still, SEC filings show that on May 13 ’25, Topper James N (Director) acquired 1,120 shares at an average price of $3.16 for $3543.0. The insider now directly holds 49,323 shares of Phathom Pharmaceuticals Inc (PHAT).
